Viraspec AB ("Viraspec") announces today that the company has been accepted to the SmiLe Incubator (“SmiLe”) in Lund, Sweden. Viraspec is a newly formed start-up committed to accelerating the development of a cost-effective and rapid diagnostic test for COVID-19 that provides results in roughly 5 minutes and will be suitable for at-home use.
Viraspec was founded in March of 2020 by a group of experienced entrepreneurs in the biotechnology, diagnostics and start-up space in response to the COVID-19 pandemic. The company is committed to
developing and commercialising a novel rapid diagnostic test for COVID-19 that is faster, less expensive, easier to use, more reliable, more accurate, and able to triage risk groups and those needing immunisation. Much like a pregnancy test, Viraspec’s test will also be suitable for at-home use and is based on a lateral flow assay, however in this case using a drop of blood. What is unique with the test is that it can measure both the COVID-19 antibody as well as a persons ability to manage the viral load, and thus can be considered more informative.
Robert Porter, CEO for Viraspec, comments “Basing Viraspec in SmiLe will provide the necessary environment and resources to accelerate our time to market, and will give us access to key networks in the healthcare space to validate our technology. Time is of the essence with any pandemic and we are confident that our association with SmiLe will play a decisive roll in helping us quickly bring our novel COVID-19 diagnostic test into hands of people. Being able to rapidily and reliably test and monitor those who need medical assistance versus a vaccine or self isolation, will create the transparency needed to build confidence among people and return to a normal life. Looking to the future we will keep a keen eye out for future pandemic threats and other viral infections and use our experience to swiftly provide a rapid test to necessary areas.”
Ebba Fåhraeus, CEO for SmiLe, comments “I am very happy to welcome Viraspec into SmiLe and look forward to following the company’s progress as they develop a much needed diagnostic test for the COVID-19 pandemic. Since Virospec´s diagnostic test can measure the COVID-19 antibody as well as a person’s ability to manage the viral load, this will prove to be a very useful triage tool, especially as governments begin to lift quarantine restrictions and attempt to restart economic activity.”
For further information:
Robert Porter, CEO
Tel: +44 7597 399832
Viraspec AB is developing and commercialising a novel rapid diagnostic test for COVID-19 that is faster, less expensive, easier to use, more reliable, more accurate, and able to triage risk groups and those needing immunisation. www.viraspec.com